They generated returns above their cost of capital for the first time in four years.

Role of health reinsurance modest relative to other lines, but significant growth continues.

Hard pricing conditions likely to last longer than in previous cycles.

New companies fail to form, despite hard market conditions.

The American company, active in Canada, has divested several segments over the past 18 months.

Appropriate mortality assumptions for pricing new reinsurance remain unclear.

The technology also presents new ethical dilemmas.